Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517485 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
A Phase 1 study of Platinum-resistant Ovarian Cancer and Non-Small Cell Adenocarcinoma, sponsored by Mersana Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT06517485 is a Phase 1 study of Platinum-resistant Ovarian Cancer and Non-Small Cell Adenocarcinoma that has completed, run by Mersana Therapeutics. The registered enrollment target is 142 participants, below the 178-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06517485, a Phase 1 study of Platinum-resistant Ovarian Cancer and Non-Small Cell Adenocarcinoma, has completed, sponsored by Mersana Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. In addition to safety assessments, the pharmacokinetics of the drug were assessed along with ADC activity.
Conditions Studied
Interventions
- DRUG upifitamab rilsodotin
Study Locations (1)
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06517485
The ClinicalTrials.gov registry entry for NCT06517485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (20% lower). The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which upifitamab rilsodotin is the first listed.
NCT06517485 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06517485 about?
NCT06517485 is a clinical study titled "First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b". First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the ex...
What is the current status of trial NCT06517485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2019-07-30. Estimated completion is 2022-08-03.
What conditions does trial NCT06517485 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma.
What interventions are being tested in trial NCT06517485?
The interventions under investigation include: upifitamab rilsodotin (DRUG).
Who is sponsoring clinical trial NCT06517485?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517485 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RECRUITING · Phase 1
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Platinum-resistant Ovarian Cancer
All registered trials for this condition
Non-Small Cell Adenocarcinoma
All registered trials for this condition
Oklahoma
All trials with a study site in Oklahoma
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.